RxDoctor Payments Data

Matthew Ward, MD

Ophthalmology · Iowa City, IANPI 1023251881

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (37.6%), charitable contributions and consulting fees — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Microsurgical Technology, Inc. at 36.4% of the total. Reporting peaked in 2023 at $2,138 and has fallen 53.9% since, to $986 in 2025.

$4,376in general payments, 2019–2025

Across 22 payments — averaging $198.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Microsurgical Technology, Inc.$2K
  • Lumenis BE Inc$849
  • Digital Diagnostics Inc.$700
  • Rxsight Inc$426
  • Merakris Therapeutics, Inc.$396
  • Alcon$134
  • plus $276 from 6 others
$9,600in research payments, 2019–2025

Across 3 payments — averaging $3200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Rxsight Inc$10K

What the payments were for

  • Consulting fees$70016%
  • Speaking & faculty fees$43510%
  • Food & beverage$1,64638%
  • Charitable contribution$1,59536%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,376 in reported general payments places this provider in the 80th percentile of 172 ophthalmology providers in Iowa.

See all ophthalmology providers in Iowa

Medicare billing

Part B allowed, 2024
$301,467
Medicare patients
362
Services billed
1,316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj12$560,284
RestasisCyclosporine26$21,724
Fluorometholone150$12,170
Prednisolone Acetate152$6,663
LumiganBimatoprost11$6,558
RhopressaNetarsudil Mesylate14$4,411
Doxycycline Monohydrate192$3,752
Tobramycin-DexamethasoneTobramycin/Dexamethasone41$1,887
Latanoprost154$1,698
ValacyclovirValacyclovir Hcl48$1,370
Difluprednate12$1,335
Acyclovir76$1,310
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat39$739
Timolol Maleate49$424
Doxycycline Hyclate18$401

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Iowa City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →